Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Dividends Paid - Common (2021 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Dividends Paid - Common for 5 consecutive years, with $344000.0 as the latest value for Q3 2025.

  • Quarterly Dividends Paid - Common fell 15.27% to $344000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2025, down 28.8% year-over-year, with the annual reading at $1.2 million for FY2025, 28.8% down from the prior year.
  • Dividends Paid - Common hit $344000.0 in Q3 2025 for Ani Pharmaceuticals, down from $407000.0 in the prior quarter.
  • In the past five years, Dividends Paid - Common ranged from a high of $407000.0 in Q2 2022 to a low of $190000.0 in Q4 2021.
  • Historically, Dividends Paid - Common has averaged $388875.0 across 5 years, with a median of $406000.0 in 2022.
  • Biggest five-year swings in Dividends Paid - Common: skyrocketed 114.21% in 2022 and later dropped 15.27% in 2025.
  • Year by year, Dividends Paid - Common stood at $190000.0 in 2021, then soared by 114.21% to $407000.0 in 2022, then dropped by 0.25% to $406000.0 in 2023, then changed by 0.0% to $406000.0 in 2024, then fell by 15.27% to $344000.0 in 2025.
  • Business Quant data shows Dividends Paid - Common for ANIP at $344000.0 in Q3 2025, $407000.0 in Q2 2025, and $406000.0 in Q1 2025.